Earnings summaries and quarterly performance for Arcus Biosciences.
Executive leadership at Arcus Biosciences.
Board of directors at Arcus Biosciences.
AP
Andrew Perlman
Detailed
Director
AR
Antoni Ribas
Detailed
Director
DL
David Lacey
Detailed
Director
DB
Dietmar Berger
Detailed
Director
JM
Johanna Mercier
Detailed
Director
KF
Kathryn Falberg
Detailed
Director
LH
Linda Higgins
Detailed
Director
NL
Nicole Lambert
Detailed
Director
PM
Patrick Machado
Detailed
Director
YK
Yasunori Kaneko
Detailed
Lead Independent Director
Research analysts who have asked questions during Arcus Biosciences earnings calls.
Daina Graybosch
Leerink Partners
4 questions for RCUS
Also covers: AFMD, BNTX, CGEN +6 more
YN
Yigal Nochomovitz
Citigroup Inc.
4 questions for RCUS
Also covers: ALDX, APLS, ARCT +22 more
Jonathan Miller
Evercore ISI
3 questions for RCUS
Also covers: APLS, ARVN, ATRA +8 more
LW
Li Wang Watsek
Cantor Fitzgerald
3 questions for RCUS
Also covers: AFMD, ALXO, ARVN +7 more
PL
Peter Lawson
Barclays PLC
3 questions for RCUS
Also covers: ADAP, ARVN, BPMC +15 more
Asthika Goonewardene
Truist Securities
2 questions for RCUS
Also covers: ALLO, AUTL, BNTX +9 more
Eva Fortea-Verdejo
Wells Fargo Securities
2 questions for RCUS
Also covers: EXEL, KNSA, KYMR
Jason Zemansky
Bank of America
2 questions for RCUS
Also covers: ABOS, BBIO, CYTK +5 more
Salveen Richter
Goldman Sachs
2 questions for RCUS
Also covers: ACAD, AGIO, ALLO +20 more
Emily Bodnar
H.C. Wainwright & Co.
1 question for RCUS
Also covers: AGEN, AGIO, ATOS +6 more
Karina Rabayeva
Truist Securities
1 question for RCUS
Also covers: AUTL, CGEN, MRSN +1 more
KP
Kaveri Pohlman
BTIG, LLC
1 question for RCUS
Also covers: MDGL, MGNX, NUVB +3 more
Terence Flynn
Morgan Stanley
1 question for RCUS
Also covers: ABBV, AMGN, ARVN +17 more
UR
Umer Raffat
Evercore ISI
1 question for RCUS
Also covers: ALKS, AMGN, BHC +15 more
Recent press releases and 8-K filings for RCUS.
Arcus Biosciences Outlines 2026 Plans and Financial Outlook
RCUS
New Projects/Investments
Guidance Update
- Arcus Biosciences' highest priorities for 2026 include the rapid enrollment of its PEAK-1 Phase 3 study evaluating casdatifan in IO-experienced ccRCC patients and the initiation of a first-line Phase 3 study for casdatifan.
- The company plans at least three data presentations for casdatifan in 2026, including updated data from the Phase 1/1b ARC-20 study in February, updated data for casdatifan plus cabozantinib mid-year, and data from multiple ARC-20 cohorts in the second half of the year.
- Arcus expects its first development candidate for inflammatory and autoimmune diseases, an oral MRGPRX2 antagonist, to enter clinical development in 2026.
- With approximately $1 billion of cash and investments, Arcus anticipates being able to fund its planned operations until at least the second half of 2028.
3 days ago
Arcus Biosciences Discontinues Phase 3 STAR-221 Study and Shifts R&D Focus
RCUS
New Projects/Investments
Guidance Update
- Arcus Biosciences has discontinued its Phase 3 STAR-221 study, conducted in partnership with Gilead Sciences, Inc., due to futility based on an interim analysis of overall survival in upper gastrointestinal cancers.
- The company will now concentrate its R&D investment and resources on casdatifan, a potential best-in-class HIF-2a inhibitor, and its emerging small molecule inflammation and immunology (I&I) programs.
- Multiple data readouts for casdatifan are anticipated in 2026, alongside the expected entry of a small molecule targeting MRGPRX2 into the clinic in the same year as part of its I&I portfolio.
- Arcus expects to be able to fund its planned operations until at least the second half of 2028, supported by approximately $1 billion in cash and investments.
Dec 12, 2025, 1:30 PM
Arcus Highlights Casdatifan as Key Value Driver and Provides Pipeline Updates
RCUS
New Projects/Investments
Guidance Update
- Casdatifan, Arcus's HIF-2 inhibitor, is positioned as the biggest value driver, with 100% ownership and clinical data showing PFS over 12 months in late-line settings, significantly outperforming Merck's belzutifan (5.6 months).
- The company has three programs in Phase III, including casdatifan, an anti-TIGIT program, and a CD73 inhibitor.
- The anti-TIGIT program (STAR-221) in upper GI cancers, fully enrolled in June 2024, is expected to read out in 2026, with Phase II data indicating overall survival greater than two years compared to 12-13 months for standard of care.
- Arcus maintains a strong financial position with over $1 billion in cash, sufficient to fund initial Phase III readouts for all programs.
- A decision on the optimal casdatifan combination for a frontline Phase III study is anticipated in the second half of next year (2026), following ongoing "bake-off" studies.
Dec 3, 2025, 3:30 PM
Arcus Provides Updates on Casdatifan, Anti-TIGIT, and Pipeline Programs
RCUS
New Projects/Investments
Guidance Update
- Arcus's lead asset, Casdatifan (CAS), a HIF-2 inhibitor, is positioned as a major value driver due to its 100% ownership and demonstrated superior clinical profile compared to Merck's Belzutifan, with a PFS of over 12 months versus 5.6 months in late-line settings.
- The company is advancing CAS into two Phase III studies for clear cell RCC, with the CAS+CABO combination study aiming to complete enrollment by the end of 2026 , and a decision on the best frontline combination for a Phase III study expected by the second half of 2026.
- Arcus's anti-TIGIT program, Domvanalimab, has its first Phase III study (STAR-221) in upper GI cancers, which was fully enrolled in June 2024 and is expected to read out in 2026. This program features an Fc silent configuration, believed to offer a better safety profile.
- The company also fully enrolled its Phase III study (PRISM1) for its CD73 inhibitor, Quemliclustat, in September 2025, ahead of schedule. Arcus maintains a strong financial position with over $1 billion in cash, covering initial Phase III readouts for all programs.
Dec 3, 2025, 3:30 PM
Arcus Biosciences Highlights Key Pipeline Assets and 2026 Milestones
RCUS
New Projects/Investments
Guidance Update
- Arcus Biosciences' primary focus is casdatifan, a HIF-2 inhibitor, which has shown promising early data compared to Belzutifan, with more data expected in 2026 to inform its Phase III strategy.
- The Phase III STAR-221 study for Domvanalimab (anti-TIGIT), which showed differentiated overall survival data in earlier studies, is anticipated to read out in 2026.
- The Phase III study for Quemli (CD73 inhibitor) was fully enrolled in September, with a readout expected based on the typical overall survival of the control arm.
- Arcus Biosciences has over $1 billion in capital to execute on its pipeline programs.
- Enrollment for the Volrustomig (bispecific) combo study was paused due to adverse events, with ongoing assessment of current patients.
Dec 2, 2025, 9:40 PM
Arcus Provides Updates on Key Clinical Programs and Strategic Focus
RCUS
New Projects/Investments
Guidance Update
- Casdatifan (HIF-2 inhibitor) is a primary focus, with significant data expected in 2026 to define its Phase 3 strategy in the second half of the year, showing superior data compared to belzutifan.
- The anti-TIGIT program (DAM) has its Phase 3 STAR-221 study (1,050 patients) expected to read out in 2026, having been fully enrolled in June 2024. Additionally, the STAR-121 study (1,000 patients) will be fully enrolled by the end of 2025.
- Arcus anticipates presenting more mature data for its casdatifan plus CABL combination next year, covering the full 44-patient dataset, which previously demonstrated a 40%+ response rate.
- The company reported having $1 billion+ to execute its programs, and its CD73 inhibitor (Quemly) Phase 3 study was fully enrolled in September.
- Enrollment for the Volroo combo was paused due to early AEs resembling CTLA-4 AEs, and the company is evaluating potential protocol amendments.
Dec 2, 2025, 9:40 PM
Arcus Biosciences Highlights Key Pipeline Assets and Upcoming Milestones
RCUS
New Projects/Investments
Guidance Update
- Casdatifan, an HIF-2 inhibitor, is a primary strategic focus for 2026, with data showing superior efficacy compared to Belzutifan and plans for more data and a Phase III strategy definition next year.
- The company anticipates significant Phase III readouts for Domvanalimab (anti-TIGIT), including STAR-221 in 2026 for GI cancers, and full enrollment of STAR-121 for NSCLC by the end of 2025.
- The Phase III study for Quemli (CD73 inhibitor) fully enrolled in September 2025, with a potential readout timeline based on the standard overall survival for the comparator arm.
- Arcus Biosciences possesses over $1 billion in capital to advance its pipeline programs.
Dec 2, 2025, 9:40 PM
Arcus Biosciences, Inc. Completes Public Offering of Common Stock
RCUS
- Arcus Biosciences, Inc. entered into an underwriting agreement on October 30, 2025, for a public offering of its common stock.
- The company issued and sold a total of 15,755,000 shares of common stock, including the full exercise of the underwriters' option, at a public offering price of $18.25 per share.
- The offering closed on November 3, 2025, resulting in net proceeds of approximately $269.7 million for the company.
Nov 3, 2025, 9:17 PM
Arcus Biosciences Prices $250 Million Public Stock Offering
RCUS
- Arcus Biosciences announced the pricing of an underwritten public offering of 13,700,000 shares of its common stock at $18.25 per share.
- The offering is expected to generate $250 million in gross proceeds for Arcus Biosciences.
- The underwriters have been granted a 30-day option to purchase up to 2,055,000 additional shares of common stock.
- The offering is anticipated to close on November 3, 2025, subject to customary closing conditions.
Oct 31, 2025, 3:35 AM
Arcus Biosciences Reports Q3 2025 Financial Results and Pipeline Updates
RCUS
Earnings
Guidance Update
New Projects/Investments
- Arcus Biosciences reported Q3 2025 revenues of $26 million and a net loss of $135 million, compared to revenues of $48 million and a net loss of $92 million in Q3 2024. The company anticipates full year 2025 GAAP revenue between $225 million and $235 million.
- The company concluded Q3 2025 with $841 million in cash, cash equivalents, and marketable securities, down from $992 million at December 31, 2024, and projects this capital will fund operations through initial pivotal readouts for its main programs.
- Casdatifan demonstrated 12.2 months median progression-free survival (mPFS) and an 18-month landmark PFS of 43% in a pooled analysis of 121 patients with late-line kidney cancer from the ARC-20 study, with further data expected in 2026. Additionally, domvanalimab plus zimberelimab and chemotherapy achieved a median overall survival (OS) of 26.7 months in first-line upper gastrointestinal adenocarcinomas.
- In October, Taiho exercised its option for an exclusive license to casdatifan in Japan and certain territories in Asia. Arcus also unveiled a portfolio of five programs targeting inflammatory and autoimmune diseases, with a small molecule targeting MRGPRX2 expected to enter the clinic in 2026.
Oct 28, 2025, 8:08 PM
Quarterly earnings call transcripts for Arcus Biosciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more